Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

440.42 +4.49 (+1.03%)
Streaming Delayed Price Updated: 10:44 AM EDT, May 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
73 74 Next >
News headline image
Is Vertex Pharmaceuticals Gaining or Losing Market Support? ↗
 
Via Benzinga
News headline image
Demystifying Vertex Pharmaceuticals: Insights From 17 Analyst Reviews ↗
 
Via Benzinga
News headline image
Vertex Discontinues Development Of Type 1 Diabetes Candidate After Disappointing Data ↗
Vertex halts VX-264 trials after missing efficacy goals but continues advancing zimislecel, a potential treatment for severe type 1 diabetes, toward approval. 
Via Benzinga
News headline image
Technical Signals Point to a Possible Breakout for VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX). ↗
Exploring VERTEX PHARMACEUTICALS INC's Technical Signals and Breakout Potential: Based on good technical signals, VERTEX PHARMACEUTICALS INC is potentially setting up for a breakout. 
Via Chartmill
News headline image
Vertex Announces Program Updates for Type 1 Diabetes Portfolio
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
If I Could Buy Only 1 Growth Stock, This Would Be It ↗
Via The Motley Fool
News headline image
Is Vertex Pharmaceuticals Gaining or Losing Market Support? ↗
 
Via Benzinga
News headline image
Netflix, Vertex Pharmaceuticals And More On CNBC's 'Final Trades' ↗
 
Via Benzinga
News headline image
Rattled by the Stock Market Sell-Off? These 3 Stocks Outperformed the S&P 500 During the Great Recession ↗
Via The Motley Fool
Topics Economy Government Stocks
News headline image
Merck's Biggest Moneymaker Could Get Even Bigger. But Will It Help Downtrodden Shares? ↗
The FDA is due to make an approval decision in mid-September for a key product from the top pharma company. 
Via Investor's Business Daily
News headline image
$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
Q4 Rundown: Biogen (NASDAQ:BIIB) Vs Other Therapeutics Stocks
Let’s dig into the relative performance of Biogen (NASDAQ:BIIB) and its peers as we unravel the now-completed Q4 therapeutics earnings season. 
Via StockStory
Topics Artificial Intelligence
News headline image
Nasdaq Sell-Off: 2 Brilliant Stocks to Buy No Matter What the Market Does Next ↗
Via The Motley Fool
News headline image
A Look Back at Therapeutics Stocks’ Q4 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) Vs The Rest Of The Pack
Let’s dig into the relative performance of Vertex Pharmaceuticals (NASDAQ:VRTX) and its peers as we unravel the now-completed Q4 therapeutics earnings season. 
Via StockStory
Topics Artificial Intelligence
News headline image
3 Unstoppable Stocks You Can Buy Now Without Any Hesitation ↗
Via The Motley Fool
News headline image
3 No-Brainer Healthcare Stocks to Buy With $1,000 Right Now ↗
Via The Motley Fool
News headline image
$100 Invested In Vertex Pharmaceuticals 5 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
3 Stocks With Ironclad Balance Sheets for Long-Term Stability
Check out these three stocks with balance sheets that have a case for being among the strongest in the entire stock market. 
Via MarketBeat
Topics Economy Supply Chain
News headline image
VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX) is showing promising signs of setting up for a breakout. ↗
Exploring VERTEX PHARMACEUTICALS INC's Technical Signals and Breakout Potential: Based on good technical signals, VERTEX PHARMACEUTICALS INC is potentially setting up for a breakout. 
Via Chartmill
News headline image
Top 3 Health Care Stocks That May Keep You Up At Night In Q1 ↗
 
Via Benzinga
News headline image
Nasdaq Correction: The 2 Smartest Stocks to Buy and Hold Forever ↗
Via The Motley Fool
News headline image
3 Reasons to Avoid VRTX and 1 Stock to Buy Instead
Vertex Pharmaceuticals trades at $500.94 and has moved in lockstep with the market. Its shares have returned 5.5% over the last six months while the S&P 500 has gained 1.6%. 
Via StockStory
Topics Stocks
News headline image
Where Will Vertex Pharmaceuticals Be in 10 Years? ↗
Via The Motley Fool
News headline image
Which S&P500 stocks are moving on Monday? ↗
Curious about the S&P500 stocks that are in motion on Monday? Join us as we explore the top movers within the S&P500 index during today's session. 
Via Chartmill
News headline image
3 Magnificent Growth Stocks to Buy in March ↗
Via The Motley Fool
News headline image
Vertex Newly Approved Pain Treatment Lands Higher Cost Tier 3 Placement In UnitedHealth's Optum Rx Formularies ↗
Vertex's Journavx, a new non-opioid pain drug, lands Tier 3 on Optum Rx formularies. Vertex reports $2.91 billion Q4 sales. 
Via Benzinga
News headline image
Cannabis For Pain Relief: Scientists Develop New Compound Without Mind-Altering Effects — Alternative To Opioids? ↗
New compound mimics natural molecule in cannabis plant, providing pain relief without addictive side effects. 
Via Benzinga
Topics Cannabis
News headline image
Good technical signals and a possible breakout for VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX). ↗
VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX) has a strong technical rating of 9 out of 10, indicating a potential breakout. 
Via Chartmill
News headline image
5 Top Stocks to Buy in March ↗
Via The Motley Fool
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
73 74 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.